An Overview: Appropriate Applications of PO and IV Therapy with Levofloxacin for Patients with Lower Respiratory Tract Infections
Charles M. Fogarty, MD
Spartanburg Pharmaceutical Research, Spartanburg, SC, USA
The appropriate use of levofloxacin, either IV or PO, in lower respiratory tract infections (LRTI's) requires two strategies: avoidance of situations where use is inappropriate and selection of situations where use offers significant superiority in terms of efficacy, safety or cost. Key to avoiding inappropriate use is awareness that many patients presenting with respiratory complaints may have a viral or other etiology for their symptoms or chest film infiltrates. Key to appropriate use is recognition that given the increasing incidence of penicillin and macrolide resistant Streptococcus pneumoniae,-lactamase resistant Haemophilus influenzae and Moraxella catarrhalis, and given the increasing role of atypical pathogens and copathogens, only quinolones such as levofloxacin provide safe and effective monotherapy, either IV or PO, in both inpatient and outpatient settings.